SCHEMBL6137231

SCHEMBL6137231

CCOC(=O)c1c(C)nc(C)c(C#N)c1-c1cccc(C#N)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.60
L3MBTL1 Q9Y468 2/20 0.60
SMN1; SMN2 Q16637 3/20 0.59
GAA P10253 3/20 0.56
NPSR1 Q6W5P4 2/20 0.56
LMNA P02545 2/20 0.56
MAPT P10636 2/20 0.56
KDM4E B2RXH2 1/20 0.56
NPC1 O15118 1/20 0.56
HPGD P15428 1/20 0.56
RAB9A P51151 1/20 0.56
FNTA P49354 2/20 0.55
FNTB P49356 2/20 0.55
CNR2 P34972 1/20 0.50
HTT P42858 3/20 0.48
RXFP1 Q9HBX9 1/20 0.48
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
POLB P06746 1/20 0.47
TLR8 Q9NR97 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6137171 0.87 ALDH1A1 (0.58) ALDH1A1L3MBTL1SMN1; SMN2GAANPSR1
SCHEMBL6137339 0.85 ALDH1A1 (0.56) ALDH1A1L3MBTL1SMN1; SMN2GAANPSR1
SCHEMBL6137255 0.84 SMN1; SMN2 (0.56) ALDH1A1L3MBTL1SMN1; SMN2GAANPSR1
SCHEMBL6137213 0.82 ALDH1A1 (0.54) ALDH1A1L3MBTL1SMN1; SMN2GAANPSR1
SCHEMBL6137355 0.81 ALDH1A1 (0.56) ALDH1A1L3MBTL1SMN1; SMN2GAANPSR1
SCHEMBL8928263 0.81 ALDH1A1 (0.52) ALDH1A1L3MBTL1SMN1; SMN2GAANPSR1
SCHEMBL8928258 0.80 ALDH1A1 (0.51) ALDH1A1L3MBTL1SMN1; SMN2GAANPSR1
SCHEMBL10377682 0.78 KDM4E (0.58) ALDH1A1L3MBTL1SMN1; SMN2GAANPSR1
SCHEMBL9779236 0.78 ALDH1A1 (0.48) ALDH1A1L3MBTL1SMN1; SMN2GAANPSR1
SCHEMBL9779447 0.77 SMN1; SMN2 (0.45) ALDH1A1L3MBTL1SMN1; SMN2GAANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1372657-A4 A METHOD OF TREATING PROLIFERATIVE DISEASES USING EG5 INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2005-11-09 EP disclosed
EP-1372657-A2 A METHOD OF TREATING PROLIFERATIVE DISEASES USING EG5 INHIBITORS Bristol-Myers Squibb Company (US) 2004-01-02 EP disclosed
WO-2002078639-A2 A METHOD OF TREATING PROLIFERATIVE DISEASES USING EG5 INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2002-10-10 WO disclosed